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Abstract
Purpose Using current optical imaging techniques and gamma imaging modalities, perioperative sentinel lymph node (SLN)
identification in colon cancer can be difficult when the SLN is located near the primary tumour or beneath a thick layer of (fat)
tissue. Sentinel lymph nodemapping using PET/CT lymphoscintigraphy combined with real-time visualization of the SLN using
near-infrared imaging has shown promising results in several types of cancer andmay facilitate the successful identification of the
number and location of the SLN in early colon cancer.
Methods Clinical feasibility of PET/CT lymphoscintigraphy using preoperative endoscopically injected [89Zr]Zr-Nanocoll and
intraoperative injection of the near-infrared (NIR) tracer Indocyanine Green (ICG) was evaluated in ten early colon cancer
patients. Three preoperative PET/CT scans and an additional ex vivo scan of the specimen were performed after submucosal
injection of [89Zr]Zr-Nanocoll. All SLNs and other lymph nodes underwent extensive pathological examination for metastases. A
histopathological proven lymph node visible at preoperative PET/CT and identified at PET/CT of the specimen was defined as
SLN.
Results A total of 27 SLNs were harvested in seven out of eight patients with successful injection of both tracers. In one patient
no SLNs were assigned preoperatively. In two patients injection of [89Zr]Zr-Nanocoll failed due to incorrect needle positioning.
Twenty-one (78%) SLNs were found intraoperatively using NIR-imaging. Eleven of the 27 (41%) SLNs were located near the
primary tumour (< 2 cm). Those six SLNs not found intraoperatively with NIR-imaging were all located close to the tumour. In
all seven patients at least one SLN could be assigned at preoperative imaging 24 h after tracer administration. One SLN contained
metastases detected by immunohistochemistry. No metastases were found in the non-SLNs.
Conclusions This study shows the potential of preoperative PET/CT lymphoscintigraphy to inform the surgeon about the number
and location of SLNs in patients with early colon cancer. The additional use of NIR-imaging allows for intraoperative identifi-
cation of these SLNs which are invisible with conventional white light imaging. Further research is necessary to improve and
simplify the technique. We recommend perioperative SLN identification using a preoperative lymphoscintigraphy scan just
before surgery approximately 24 h after injection. Additionally a postoperative scan of the specimen combined with intraoper-
ative real-time NIR-imaging should be performed.
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Introduction
Colorectal cancer (CRC) is the second most common malig-
nancy in the Western world and the fourth leading cancer-
related cause of death worldwide [1]. Lymph node involve-
ment is still the strongest prognostic factor and serves as the
most important selection criterion for adjuvant chemotherapy
[2]. The introduction of CRC screening programs will in-
crease the number of early staged CRC (T1-T2 disease) [3,
4]. The low risk of lymph node metastases in these early
staged tumours makes local excision of the primary tumour
an attractive treatment option [5]. However, uncertainty re-
garding undetected lymph node metastases makes current
treatment of segmental resection with en-bloc resection of
lymph nodes unavoidable in early CRC. Despite complete
surgical resection, up to 20 to 30% of patients with early
CRC show disease recurrence and eventually die within five
years of initial treatment [6, 7]. This high recurrence rate in
node negative patients is probably the result of understaging
due to missed metastases in lymph nodes during routine his-
topathological examination [8–10]. Conversely, the majority
of patients with true negative lymph nodes are exposed to
unnecessary surgery-related morbidity and mortality at rates
of up to 13.5 and 2.0%, respectively [11]. Sentinel lymph node
(SLN) identification could offer a solution by detecting the
lymph nodes with the most direct drainage from the primary
tumour and therefore with the greatest chance of harbouring
metastases.
In melanoma and breast cancer, SLN biopsies are routinely
performed using a combination of preoperative colloid
SPECT lymphoscintigraphy and perioperative guidance by
gamma-probe and preoperatively injected blue dye. The com-
bination of these techniques allows for preoperative identifi-
cation of the number and location of the SLNs, and real-time
identification of the SLNs versus surrounding fat [12–15].
SLN identification in colon cancer seems more challenging
than in breast cancer and melanoma. Firstly, SLNs of the co-
lon are more often smaller (˂ 1 cm), located beneath a thick
layer of (fat) tissue and not visible with conventional white
light imaging. Secondly, number and location of SLNs of
colon carcinoma are less predictable. Additionally, it seems
that more than one node can be assigned as SLN frequently
and they appear to be often located near the tumour. An addi-
tional difficulty of SLN identification in colon cancer is the
absence of the intraoperative sense of touch since laparoscopy
is the preferred surgical approach for colon resections. These
drawbacks underline the need for a high quality optic tracer.
The limited resolution of planar or SPECT scintigraphy may
preclude proper preoperative SLN identification due to the
shine-through effect from the tracer depot [16, 17].
Intraoperative identification is difficult because blue dye can-
not be seen through fatty tissue and its relatively small particle
size causes rapid passage through lymphatic channels,
limiting its usefulness in detecting the earliest tumour draining
lymph nodes [18, 19].
Near-infrared fluorescent tracers, and especially
Indocyanine Green (ICG), exhibit more favourable character-
istics for intraoperative detection of SLNs compared to blue
dye (e.g. larger particle size and real-time, high/resolution op-
tical guidance) [20]. PET scanners have a better spatial reso-
lution than conventional gamma imaging modalities, and al-
low for dynamic 3D imaging. In oral cancer patients, [89Zr]Zr-
Nanocoll PET/CT provided detailed anatomical localization
of tracer-foci and potentially improved identification of the
SLNs even when they were located near the injection spot
[21]. In colorectal cancer preoperative surgical planning using
PET/CT combined with real-time NIR-staining of the SLNs
using ICG might offer a solution for successful SLN biopsy.
The main purpose of this study was to establish if preoper-
ative [89Zr]Zr-Nanocoll PET/CT imaging is a useful technique
to identify the number and location of SLNs in early colon
cancer. Concordance and accuracy between number, location
and histopathological outcomes of preoperative and postoper-
ative assigned SLNs at PET/CT imaging and intraoperative
identified SLNs using real-time fluorescent NIR-imaging are
determined.
Secondly, we aimed to investigate the pharmacokinetics of
[89Zr]Zr-Nanocoll to optimize the logistics of SLN biopsies
involving radiolabelled nanocolloid.
Materials and methods
Patients
Patients were eligible if at least 18 years of age and scheduled
for a laparoscopic resection of a histopathologically proven
colon carcinoma or suspected malignant lesion seen during
colonoscopy. Oral and written consent was mandatory for
inclusion.
Exclusion criteria were reduced physical condition (ASA
IV), suspected or proven lymph node involvement or distant
metastases seen on routine preoperative imaging (CT-scan), a
tumour too large to pass endoscopically, claustrophobia and
allergy for iodine. The Medical Ethics Committee of the
Amsterdam UMC–Vrije Universiteit Amsterdam and the
National Competent Authority approved the study. The study
is registered in the Clinical Trial database (NCT02850783).
Study design
The study protocol (Fig. 1) consisted of three preoperative
PET/CT scans after injection of 0.4 mL median 2.12 (1.69–
2.85) MBq [89Zr]Zr-Nanocoll approximately 46 (43–48) hrs
before surgery and intraoperative injection of ICG. Detailed
information concerning the injection technique can be found
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in the supplementary material (Supplementary material 1).
The PET/CT scan nr. 1 (Ingenuity; Philips Healthcare)
consisted of 3–5 dynamic frames of 5 min each and started
circa one hour after tracer injection. Two static PET/CT im-
ages were made one day (scan nr. 2) and two days (scan nr. 3)
after tracer administration (3–5 frames, 5 min each), respec-
tively. Before surgery the results of the PET/CT images were
compared with respect to the total number, localization and
intensity of possible SLNs by a senior nuclear medicine phy-
sician (O.S.H). Results were discussed with the operating sur-
geon. A SLNwas defined when focal tracer accumulation was
evident in the mesocolon. At start of surgery after general
anaesthesia, a second colonoscopy served to inject the fluo-
rescent tracer Indocyanine Green (ICG) at the base of the
tumour using one single injection. During surgery, a NIR lap-
aroscopic device was used (Olympus; Tokyo, Japan). The
SLNs were detected by means of fluorescence and the 'hot
spot' locations preoperatively assigned at PET/CT.
Intraoperative fluorescent SLNs were marked with a suture.
All patients underwent conventional oncological laparoscopic
resection after SLN(s) marking with a suture. A fourth PET/
CT scan (scan nr. 4) of the surgical specimen was made di-
rectly after surgery to confirm correct identification of preop-
eratively identified 'hot spots' and to facilitate comparison of
PET/CT imaging and pathological findings (Fig. 2). After
identification and additional suturing of radioactive lymph
nodes found at PET/CT or with NIR- imaging, the specimen
was transferred to the Department of Pathology for examina-
tion of the specimen including all lymph nodes.
[89Zr]Zr-Nanocoll
[89Zr]Zr-Nanocoll is the PET corollary of 99mTc-Nanocoll
used for SPECT scintigraphy. Heuveling et al. [22] showed
that Nanocoll pharmacokinetics are independent of the radio-
label (either 89Zr or 99mTc) and the 78 h physical half-life of
89Zr-Nanocoll allows for flexibility in SLN observation time.
[89Zr]Zr-NCS-Bz-DFO-Nanocoll (hereafter called [89Zr]Zr-
Nanocoll) was produced according to the previously reported
method in Heuveling et al. [22] under good manufacturing
practice compliant conditions. [89Zr]Zr-Nanocoll was filter
sterilized which resulted in a sterile final product with less
than 2.5 endotoxin units/mL. The radiochemical purity was
>99.9%.
Histopathology
Examination of the specimen by the pathologist followed after
fixation of the specimen in formalin for at least 24 h. After
fixation the pathologist harvested the perioperative suture-
marked structures assigned as SLNs first and stored them sep-
arately. Thereafter, the pathologist searched for additional
lymph nodes by palpation and slicing of the whole specimen.
Round, smooth and rigid structures similar to lymph nodes
were harvested and stored separately too. Location of each
potential SLN and all non-SLNs were compared with the lo-
cations assigned at PET/CT imaging. All lymph nodes were
reassessed for fluorescence with the NIR-laparoscope and
gamma well counter to reveal radioactivity.
All harvested SLNs and non-SLNs were bisected along
the longest axis, paraffin embedded and stained with
haematoxylin & eosin (H&E). Individual SLNs were em-
bedded separately. If the lymph nodes were negative after
routine H&E staining, all nodes were sectioned (3–4 μm
thick) at 150 μm intervals and examined at three levels
with H&E-staining and immunohistochemistry with the
epithelial marker CEA (Clone 1117; DAKO Netherlands
M7072) , CAM 5.2 (3,455,799; BD Biosc iences
Netherlands) and CK19 (M0888, clone RCK 108; DAKO
The Netherlands). Metastases between 0.2 mm and 2.0 mm
were classified as micrometastases, and metastases smaller
than 0.2 mm as isolated tumour cells according to the TNM
5 classification.
Image analysis
All PET/CT scans including the PET/CT of the specimen,
were postoperatively reanalyzed and the results compared
with respect to the total number and location of foci by a
48 hrs
Injection 
[
89
Zr] Zr-Nanocoll
Dynamic 
PET-CT 1
Static 
PET-CT 2
Static 
PET-CT 3
Static PET-CT 4
of the specimen
Preoperative 
PET-CT analysis
Surgery + ICG injection
and NIR SLN mapping
Pathological examination of the 
specimen including NIR-imaging
and compugamma analysis of all 
harvested suspected LNs
0 hr 24 hrs 72 hrs
Fig. 1 Time schedule of the study protocol
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nuclear medicine physician (O.S.H) who was blinded to sur-
gical findings and pathology results.
The location of all lymph nodes found by the pathologist
were compared with pre-, and postoperatively assigned SLNs
at PET/CT imaging using Vinci software (Vinci 2.36.0; Max-
Planck-Institut fur Neurologische Forschung, Cologne,
Germany). Volumes of interest (VOI) were used to delineate
the amount of radioactivity for pharmacokinetics [23].
Definition of sentinel lymph nodes
Ahistopathological proven lymph node visible at preoperative
PET/CT and identified at PET/CT of the specimen was clas-
sified as SLN. Lymph nodes only stained by ICG or unstained
nodes identified by the pathologist were defined as other
lymph nodes.
Statistical analysis
Data were analysed using SPSS software (SPSS version 22.0;
SPSS, Inc.; Chicago, IL). Point estimates and distribution
were expressed as median and range, respectively. The
Mann-Whitney U test was performed to determine the statis-
tical significance of continuous variables. Results were con-
sidered as statistically significant at a P level of less than 0.05.
Results
We included ten patients with early colon cancer, and patient
characteristics are shown in Table 1. None of the patients
experienced any adverse reaction following [89Zr]Zr-
Nanocoll administration. In one patient (Table 2, patient 4,
foci A) an SLN with isolated tumour cells was found. This
Fig. 2 SLN identification at PET/
CT images of patient 2. Injection
side is shown as `i` in all images.
Foci A, B, C and D showed in
total five sentinel lymph nodes
and were already apparent at first
scan (0 h after injection). Foci E
represented two sentinel lymph
nodes first seen at the second
PET/CTscan (24 h after injection)
and F was first seen at the third
scan after 48 h. Lymph nodes E
and F were probably hidden be-
hind the other 'hotter' nodes. All
SLNs were intraoperatively iden-
tified using near-infrared imaging
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SLN was detected with both imaging modalities and located
>2 cm from the primary tumour. No metastases were found in
other SLNs or lymph nodes in the remaining patients. ICG
injection was successful in all patients, but [89Zr]Zr-Nanocoll
administration failed in two cases (Table 1; patients 3 and 4).
In one patient tracer had been injected through the subserosal
colonic layer in the abdominal cavity (patient 3). In another
patient injection failed due to needle luxation outside the tu-
mour during [89Zr]Zr-Nanocoll administration (patient 4).
Both resulted in low uptake of radioactivity in the primary
tumour and high background radiation due to spill in the ab-
dominal cavity or colonic lumen. Both patients were excluded
from further analysis.
At preoperative PET/CT imaging we assigned 24 potential
SLN foci (Table 2). One subdiaphragmatic and one preaortic
potential lymph node (Table 2, patient 1) were not harvested
because they were located too far from the resection margins,
which would hamper the conventional resection. Another fo-
cus was perioperative found but did not contain lymphatic
tissue (Table 2, patient 1, focus A). In this patient no other
SLNs were assigned preoperatively. After exclusion of these
three foci, a final number of 21 foci in seven out of eight
patients with successful injection of both tracers were identi-
fied. Some foci proved to contain more than one SLN, so that
these 21 foci compromised 27 true SLNs. All 21 foci were
preoperatively assigned by the nuclear medicine consultant
just before surgery. All 27 SLNs revealed fluorescence of
which 21 (78%) were detected intraoperatively using NIR-
imaging. Eleven of the 27 (41%) SLNs were located near
the primary tumour (< 2 cm). Those six SLNs not found in-
traoperatively with NIR-imaging were all located close to the
tumour.
An additional 14 lymph nodes were identified at PET/CT
imaging of the specimen. All revealed fluorescence of which
ten were identified by intraoperative NIR-imaging. Six out of
these 14 lymph nodes were located near the primary tumour;
three were only visible at PET/CTof the specimen and another
three with both imaging modalities. Another ten foci were
only intraoperatively identified with NIR imaging. Four of
these fluorescent foci contained fat tissue (patient 1; foci B,
C, D, E). The remaining foci revealed six lymph nodes all of
which were located far from the primary tumour.
All specimens were submitted for pathological examina-
tion. An additional 172 suspected lymph nodes were harvest-
ed from the specimen by the pathologist. Histopathological
examination showed 102 true lymph nodes. Fat or blood ves-
sels were found at 70 foci of which 15 showed fluorescence
probably as a result of dye leakage after disruption of lym-
phatic vessels during specimen extraction.
Of the 102 true lymph nodes, 41 nodes (40%) showed
fluorescence with radioactivity counts of 14.3 10−3[0.36–
13.3−3] MBq/node and 0.97 [0.028–9.1] %ID/node, which
was significantly lower than the SLN radioactivity; 68.3 ×
10−3[4.7–215.9−3] MBq/node and 4.7 [0.32–13.2] %ID/node,
(p = 0.0001). Mean radioactivity of lymph nodes without up-
take of ICG was 1.2 × 10−3 (0.33–8.3 × 10−3) MBq and 0.08
(0.03–0.55) %ID/node, which was significantly less than ac-
tivity in the SLNs and 41 fluorescent lymph nodes (both p =
0.0001). None of the lymph nodes additionally found in the
specimen showed metastases.
Pharmacokinetics and biodistribution
The pharmacokinetics of [89Zr]Zr-Nanocoll are shown in
Fig. 3. Pharmacokinetics were calculated using the amount
of radioactivity in seven out of the eight SLNs identified at
all PET/CT scans. Exclusion of one SLN occurred since no
reliable VOI be drawn due to its location near (< 2 cm) the
tumour. PET/CT scans were made 0.8 (0.17–1.37) hrs, 24.18
(16.07–26.62) hrs, 42.02 (40.08–42.33) hrs and 48.34 (46.2–
5.25) hrs after injection, respectively. Not all SLNs were seen
at all three preoperative PET/CT scans. Eleven SLNs were
visible at the first PET/CT scan. At the second PET/CT scan
23 SLNswere seen. One SLN seen at the first PET/CTwas not
Table 1 Basic patient characteristics
Patient Gender Age (years) BMI (kg/m2) ASA I-III Tumour side Tumour size (cm) T-stage N-stage
1 Male 74 24.1 II Sigmoid 0.5 1 N0
2 Male 67 23.0 II Sigmoid 2.8 1 N0
3 Male 65 21.9 II Flexura hepatica 4.8 3 N0
4 Male 75 36.1 III Flexura lienalis 1.0 3 N1
5 Female 65 27.4 II Cecum 3.4 2 N0
6 Male 77 23.8 II Sigmoid 3.0 2 N0
7 Male 74 23.3 II Colon ascendens 3.2 1 N0
8 Male 76 26.6 II Sigmoid 3.9 2 N0
9 Male 69 27.8 I Sigmoid 2.5 2 N0
10 Female 63 22.6 II Flexura lienalis 4.0 2 N0
Total 71.5 (63–77) 24.0 (21.9–36.1) 3.1 (0.5–4.8)
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visible at the second scan and 13 were first identified at the
second. Twenty-four SLNs were marked at the third PET/CT
just before surgery. Three SLNs seen at the second PET/CT
scan were not visible at the third scan. Another three SLNs
were first identified at this time-point. (Fig. 4).
Discussion
In the present study we demonstrated the feasibility of PET/
CT lymphoscintigraphy combined with optical real-time NIR-
imaging using [89Zr]Zr-Nanocoll and ICG to identify the
SLNs in early stage colon cancer patients. Perioperative
SLN identification succeeded in seven out of eight patients
in which a median number of three SLNs were found. All
SLNs revealed radioactivity and fluorescence, but six SLNs
were not identified with NIR-imaging intraoperatively. These
six lymph nodes were all located near (< 2 cm) the primary
tumour and were probably covered due to the shine-through
effects from the injection depot. When attempting to identify
SLNs near the tumour, our results demonstrate that PET/CT
imaging is a reliable technique, although PET/CT of the sur-
gical specimenmay improve the accuracy. Overall, these find-
ings suggest that PET/CT lymphoscintigraphy combined with
NIR-imaging could be a useful method for SLN identification
in patients with early-staged colon cancer. The preoperative
PET/CT images could guide the surgeon to the number and
location of SLNs which are currently unknown for colon can-
cer. Identification of these SLNs with NIR-imaging allows for
intraoperative detection of these SLNs which is not possible
with conventional white light imaging since SLNs are not
visible with the naked eye.
To the best of our knowledge, this is the first study using
[89Zr]Zr-Nanocoll radiocolloid and PET/CT with NIR-
imaging as SLN mapping technique in colon cancer. The ma-
jority of studies in the literature used SPECT/CT alone or in
combination with an optical tracer, typically blue dye. The
limited resolution of gamma-cameras combined with the re-
stricted visibility of blue dye through skin and fatty tissue and
its rapid distribution through lymphatic channels, makes it
difficult to detect SLNs in colon cancer, in particular since
lymphatic drainage patterns, location and number of SLNs
are unknown and unpredictable. The biodistribution data of
[89Zr]Zr-Nanocoll over time presented here, combined with
the extended pathological examination of the specimen, pro-
vided essential anatomical information on lymphatic drainage
patterns of the primary tumour towards SLNs.
The SLN procedure is based on the concept that tumour
metastases occur in an orderly and sequential manner. The
SLN(s) is/are the first lymph node(s) that receives lymphatic
drainage directly from the primary tumour and therefore has
the highest probability of harbouring metastases [24]. Based
on this theory, we hypothesized that the lymph nodes with the
highest radioactive counts ('hottest' nodes) are most likely the
first draining nodes from the primary tumour and therefore
can be considered as SLNs. These 'hottest' nodes are by def-
inition the nodes visible at PET/CT imaging. Therefore we
classified a node as SLN when it was a histopathological
proven lymph node visible at preoperative imaging and iden-
tified at PET/CT of the specimen. Similarly to breast cancer
and melanoma, more than one 'hot' node were assigned as
SLNs in all patients. This phenomenon could be attributed
to passing of the tracer through the actual SLN into other
nodes or due to divergent drainage patterns from the primary
tumour [25–27]. Not all identified SLNs were visible at PET/
CT imaging at all time points. Moreover, 14 lymph nodes
were first seen at PET/CT of the specimen and therefore not
classified as SLN. Both could be the result of physical bowel
movements which changes the anatomical position of that part
of the colon containing the injection depot and precludes SLN
detection, as visualized in Fig. 2. However, it can be argued
that lymph nodes first seen at postoperative PET/CT should
also be considered as SLNs, especially when these lymph
nodes are located near the primary tumour. For accurate
SLN identification we therefore recommend combined preop-
erative and postoperative PET/CT. The preoperative imaging
could guide the surgeon towards the SLN intraoperatively
whereas the postoperative imaging may help the pathologist
to identify additional potential SLNs to perform additional
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serial slicing and immunohistochemistry. Based on our results
we recommend one preoperative lymphoscintigraphy scan ap-
proximately 24 h after tracer injection since the majority of the
SLNs were found at the second PET/CT scan (85%) and only
three additional SLNs were found at the third PET/CT scan.
When the only aim of SLN mapping in colon cancer is im-
provement of lymph node staging, the method presented here
would not hamper introduction of the technique. For SLN
biopsy combined with local excision of the primary tumour,
this lack of a highly sensitive intraoperative SLN identifica-
tion technique is a serious drawback To improve intraopera-
tive SLN detection, intraoperative detection using a handheld
PET-probe would be desirable. Unfortunately, development of
such PET-probes is expensive and quite challenging due to
high-energy photons that need a large collimated and shielded
detector [19, 28]. Following lymph flow drainage patterns in
real-time using NIR-imaging would also be an attractive op-
tion to facilitate intraoperative detection. However, in the pres-
ent study we could not identify fluorescent lymphatic drainage
patterns. This is probably the result of the limited penetration
depth of NIR-light hampering identification of fluorescent
structures beneath a thick layer of fatty mesocolonic tissue.
Besides the limited tissue penetration of NIR-light we also
noticed the differences in lymph node identification between
NIR and PET/CT-imaging. Firstly, six SLNs located near the
primary tumour were not identified using NIR-imaging. This
failure is probably the result of tissue overlying the nodes and
background fluorescence from the primary tumour. These re-
sults suggest that PET/CT is a more reliable imaging modality
for SLN mapping in colon cancer. However we must empha-
size that the number of included patients is small and NIR-
imaging has shown to be a valuable tool to identify SLNs near
the primary tumour in several other types of cancer. Another
six intraoperatively identified lymph nodes revealed to be
fluorescent only. Although these nodes were not located near
the primary tumour nor contained metastases, it is uncertain
whether these lymph nodes are true non-SLNs. In the current-
ly used method ICG and [89Zr]Zr-nanocoll were injected sep-
arately, which could have caused different lymphatic drainage
patterns of each tracer. Thereby, a considerably higher number
of fluorescent-stained lymph nodes were found compared to
SLNs identified at PET/CT imaging. This is the consequence
of the small hydrodynamic diameter of ICG resulting in fast
migration to higher echelon lymph nodes, especially when the
time-interval between injection and SLN identification
expands.
To overcome these problems we recommend a single si-
multaneous injection of ICG combined with a radiocolloid.
Several studies have shown promising results in multiple
types of cancer using the hybrid tracer ICG-99mTc-
Nanocolloid, which allows for preoperative SPECT/CT
lymphoscintigraphy combined with intraoperative NIR-
imaging and gamma-probe guided SLN detection [29, 30].
An advantage of ICG-99mTc-Nanocolloid is the high availabil-
ity in several countries whereas [89Zr]Zr-Nanocoll has not
been FDA approved yet. The applicability of this technique
in colon cancer should be reinvestigated using knowledge
derived from the results presented here on drainage patterns
and tracer characteristics.
There were foci we classified as potential SLN at PET/CT
imaging preoperatively which were not found in the specimen
(see Table 2). Preoperative SLN identification was difficult in
several cases due to background scattering. During reassess-
ment of the PET/CT images we noticed that the majority of
these foci were in retrospect suspected to be located in the
lumen of the colon, so that some radioactive stool (due to
leakage of [89Zr]Zr-Nanocoll from the injection spot) had
been considered as SLN.
For quantification of radioactivity uptake, we calculated
the uptake of [89Zr]Zr-Nanocoll as a percentage of the injec-
tion dose per node using the gamma well counter. Due to
logistical restrictions we were not able to weigh nodes and
therefore could not express uptake levels as injected dose
per gram node (%ID/g). However, the SLNs contained the
highest amount of radioactivity compared to the other nodes,
indicating that while additional analyses using %ID/g might
have providedmore information concerning biodistribution of
[89Zr]Zr-Nanocoll, it would not have changed the results of
assigned SLNs.
An important limitation of the present study was the 20%
failure rate of [89Zr]Zr-Nanocoll injection. Correct needle
placement and careful administration of tracer with limited
spillage of dye is crucial for a successful SLN procedure.
However, submucosal injection is difficult and even more
challenging preoperatively when the patient is awake and ex-
posed to the discomfort of a colonoscopy. For accurate tracer
injection and image analysis there appears to be a steep learn-
ing curve. We therefore advocate that tracer injection should
only be performed by an experienced surgeon or gastroenter-
ologist and image analysis by a senior nuclear medicine
consultant.
Other disadvantages of the presented study were the limit-
ed number of patients, the extensive research protocol and
high costs of PET/CT imaging devices. To better determine
clinical implications a simplified protocol study including
more patients should be performed.
Conclusion
Perioperative PET/CT lymphoscintigraphy using [89Zr]Zr-
Nanocoll provides useful anatomical localization information
on SLNs in colon cancer and is able to detect nodes near the
primary tumour. Use in combination with real-time staining of
the SLN is crucial to intraoperatively identify the nodes, since
lymph nodes are not visible with conventional white light
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imaging. The limited penetration depth, the low sensitivity in
detecting SLNs near the tumour, and its fast biodistribution
are serious drawbacks of ICG for the SLN mapping technique
in colon cancer. As a consequence, pre- and postoperative
PET/CT lymphoscintigraphy is essential to disclose SLNs to
the surgeon and pathologist, respectively. Further research
should focus on simplification of the technique presented
here, and evaluation of sensitivity rates before SLN mapping
can be integrated in the daily treatment of patients with colon
cancer. For tracer administration we recommend a single sub-
mucosal injection using a composed tracer consisting of a
radiocolloid and optical dye. Perioperative SLN identification
should consist of a preoperative lymphoscintigraphy scan just
before surgery, approximately 24 h after tracer injection. We
suggest it should be combined with a postoperative scan of the
specimen and intraoperative NIR imaging to identify the pre-
operatively assigned SLNs.
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